BACKGROUND:Patients with obstructive sleep apnoea (OSA) commonly have mood symptoms such as depression and anxiety. However, the results of randomized controlled trials on the therapeutic effect of CPAP on mood symptoms have been inconsistent. The present study examined whether three weeks of CPAP treatment had specific therapeutic effects on mood symptoms in patients with OSA compared with placebo. METHODS: A double-blind, parallel, randomized controlled trial using therapeutic and placebo CPAP was performed in 71 patients newly diagnosed with OSA (apnoea-hypopnoea index [AHI]⩾10). Mood was assessed by the Center for Epidemiologic Studies-Depression (CES-D) Scale, the Profile of Mood States (POMS), and the Brief Symptom Inventory (BSI) before and after three weeks of treatment. AHI was used to assess the severity of apnoea. The two groups were compared using a simple comparison of the changes within each arm and repeated measures analysis of variance. RESULTS:Fifty-six subjects completed the study: 26 in the CPAP group and 30 in the placebo group. The two groups were well matched at baseline, with no significant differences in demographic, mood and apnoea variables. Both groups had severe apnoea, mild depression, and anxiety at baseline. After three weeks of treatment, AHI decreased significantly in the CPAP group. The mean change in AHI was -30.7 (standard deviation [SD] 23.1) in the CPAP group and -5.8 (SD 18.3) in the placebo group (difference between groups P<0.001). However, after three weeks of treatment, there were no significant time by treatment effects in relation to mood, as assessed by the CES-D, POMS Depression, POMS Tension, BSI Depression, or BSI Anxiety (all P>0.05). CONCLUSION: In conclusion, three weeks of CPAP treatment did not show a specific therapeutic effect on mood symptoms in patients with OSA. Published by Elsevier B.V.
RCT Entities:
BACKGROUND:Patients with obstructive sleep apnoea (OSA) commonly have mood symptoms such as depression and anxiety. However, the results of randomized controlled trials on the therapeutic effect of CPAP on mood symptoms have been inconsistent. The present study examined whether three weeks of CPAP treatment had specific therapeutic effects on mood symptoms in patients with OSA compared with placebo. METHODS: A double-blind, parallel, randomized controlled trial using therapeutic and placebo CPAP was performed in 71 patients newly diagnosed with OSA (apnoea-hypopnoea index [AHI]⩾10). Mood was assessed by the Center for Epidemiologic Studies-Depression (CES-D) Scale, the Profile of Mood States (POMS), and the Brief Symptom Inventory (BSI) before and after three weeks of treatment. AHI was used to assess the severity of apnoea. The two groups were compared using a simple comparison of the changes within each arm and repeated measures analysis of variance. RESULTS: Fifty-six subjects completed the study: 26 in the CPAP group and 30 in the placebo group. The two groups were well matched at baseline, with no significant differences in demographic, mood and apnoea variables. Both groups had severe apnoea, mild depression, and anxiety at baseline. After three weeks of treatment, AHI decreased significantly in the CPAP group. The mean change in AHI was -30.7 (standard deviation [SD] 23.1) in the CPAP group and -5.8 (SD 18.3) in the placebo group (difference between groups P<0.001). However, after three weeks of treatment, there were no significant time by treatment effects in relation to mood, as assessed by the CES-D, POMS Depression, POMS Tension, BSI Depression, or BSI Anxiety (all P>0.05). CONCLUSION: In conclusion, three weeks of CPAP treatment did not show a specific therapeutic effect on mood symptoms in patients with OSA. Published by Elsevier B.V.
Authors: Maree Barnes; Danielle Houston; Christopher J Worsnop; Alister M Neill; Ivanka J Mykytyn; Amanda Kay; John Trinder; Nicholas A Saunders; R Douglas McEvoy; Robert J Pierce Journal: Am J Respir Crit Care Med Date: 2002-03-15 Impact factor: 21.405
Authors: Maree Barnes; R Douglas McEvoy; Siobhan Banks; Natalie Tarquinio; Christopher G Murray; Norman Vowles; Robert J Pierce Journal: Am J Respir Crit Care Med Date: 2004-06-16 Impact factor: 21.405
Authors: R N Kingshott; M Vennelle; C J Hoy; H M Engleman; I J Deary; N J Douglas Journal: Am J Respir Crit Care Med Date: 2000-03 Impact factor: 21.405
Authors: Anne Walker; Matthew T Naughton; Lachlan Shaw; Andrew T Jeklin; Catherine Martin; Eli Dabscheck Journal: J Clin Sleep Med Date: 2021-06-01 Impact factor: 4.324
Authors: Marcus Povitz; Carmelle E Bolo; Steven J Heitman; Willis H Tsai; JianLi Wang; Matthew T James Journal: PLoS Med Date: 2014-11-25 Impact factor: 11.069
Authors: Linda D Sharples; Abigail L Clutterbuck-James; Matthew J Glover; Maxine S Bennett; Rebecca Chadwick; Marcus A Pittman; Timothy G Quinnell Journal: Sleep Med Rev Date: 2015-05-30 Impact factor: 11.609